Eton Pharmaceuticals

ETON · NASDAQ

$50.19+$0.97 (+1.97%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $49.22

Latest news

NewsOct 14, 1:34 PM ETVandana Singh
Eton Pharmaceuticals Lands Exclusive US Rights To Aquestive's Seizure Rescue Drug
Press releaseOct 14, 6:50 AM ETGlobe Newswire
Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
NewsSep 25, 4:19 PM ETChandrima Sanyal
Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach
NewsAug 27, 7:38 AM ETAvi Kapoor
Jim Cramer: 'You Could Make Some Money With This 5.6% Yield'
NewsAug 17, 2:41 AM ETAvi Kapoor
Dow Falls Over 100 Points, Records Weekly Loss: Investor Sentiment Weakens, but Fear Index Remains in ‘Greed’ Zone
NewsAug 14, 1:06 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session
NewsAug 14, 12:02 PM ETAvi Kapoor
Dow Falls Over 100 Points; US Consumer Sentiment Declines In August
NewsAug 14, 8:06 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
NewsAug 13, 5:44 PM ET
Eton Pharmaceuticals Q2 2026 Earnings Call: Complete Transcript
NewsAug 13, 5:06 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
NewsAug 13, 4:09 PM ET
Eton Pharmaceuticals Q2 Adj. EPS $0.43 Beats $0.10 Estimate, Sales $37.568M Beat $27.119M Estimate
Press releaseAug 13, 4:05 PM ETGlobe Newswire
Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results
Press releaseAug 5, 6:50 AM ETGlobe Newswire
Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001
Press releaseJul 29, 6:50 AM ETGlobe Newswire
Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution
Press releaseMay 19, 4:30 PM ETGlobe Newswire
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
NewsMay 14, 5:27 PM ET
Full Transcript: Eton Pharmaceuticals Q1 2026 Earnings Call
Press releaseMay 14, 4:05 PM ETGlobe Newswire
Eton Pharmaceuticals Reports First Quarter 2026 Financial Results
Press releaseApr 27, 6:50 AM ETGlobe Newswire
Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700
NewsMar 29, 1:10 PM ETGianni di Poce
The Insider Report: Markets Wade into Geopolitical Abyss
Press releaseMar 19, 4:05 PM ETGlobe Newswire
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Press releaseMar 2, 7:27 AM ETGlobe Newswire
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution
Press releaseNov 6, 4:05 PM ETGlobe Newswire
Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results
NewsNov 6, 6:12 AM ET
Earnings Scheduled For November 6, 2025
NewsMay 29, 12:42 PM ETVandana Singh
FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue
NewsMay 14, 2:01 PM ET
A Glimpse Into The Expert Outlook On Eton Pharmaceuticals Through 4 Analysts
NewsMay 12, 10:03 AM ET
A Look Ahead: Eton Pharmaceuticals's Earnings Forecast
NewsMar 19, 9:00 AM ET
5 Analysts Assess Eton Pharmaceuticals: What You Need To Know
NewsMar 14, 8:10 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
NewsMar 10, 8:21 AM ETAvi Kapoor
Rocket Companies, Novo Nordisk And Other Big Stocks Moving Lower In Monday's Pre-Market Session
NewsJan 8, 1:00 PM ET
The Analyst Verdict: Eton Pharmaceuticals In The Eyes Of 5 Experts
NewsNov 13, 9:00 AM ET
Analyst Expectations For Eton Pharmaceuticals's Future
NewsOct 28, 1:01 PM ET
Critical Insights From Eton Pharmaceuticals Analyst Ratings: What You Need To Know
Press releaseOct 17, 4:15 PM ETACCESSWIRE
SWK Holdings Provides Portfolio Update
NewsOct 4, 8:50 AM ETAvi Kapoor
Domino's Pizza To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Friday

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Eton Pharmaceuticals Lands Exclusive US Rights To Aquestive's Seizure Rescue Drug

Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach

Jim Cramer: 'You Could Make Some Money With This 5.6% Yield'

Dow Falls Over 100 Points, Records Weekly Loss: Investor Sentiment Weakens, but Fear Index Remains in ‘Greed’ Zone

12 Health Care Stocks Moving In Friday's Intraday Session

Dow Falls Over 100 Points; US Consumer Sentiment Declines In August

12 Health Care Stocks Moving In Friday's Pre-Market Session

Eton Pharmaceuticals Q2 2026 Earnings Call: Complete Transcript

12 Health Care Stocks Moving In Thursday's After-Market Session

Eton Pharmaceuticals Q2 Adj. EPS $0.43 Beats $0.10 Estimate, Sales $37.568M Beat $27.119M Estimate

Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results

Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001

Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)

Full Transcript: Eton Pharmaceuticals Q1 2026 Earnings Call

Eton Pharmaceuticals Reports First Quarter 2026 Financial Results

Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700

The Insider Report: Markets Wade into Geopolitical Abyss

Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution

Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results

Earnings Scheduled For November 6, 2025

FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue

A Glimpse Into The Expert Outlook On Eton Pharmaceuticals Through 4 Analysts

A Look Ahead: Eton Pharmaceuticals's Earnings Forecast

5 Analysts Assess Eton Pharmaceuticals: What You Need To Know

12 Health Care Stocks Moving In Friday's Pre-Market Session

Rocket Companies, Novo Nordisk And Other Big Stocks Moving Lower In Monday's Pre-Market Session

The Analyst Verdict: Eton Pharmaceuticals In The Eyes Of 5 Experts

Analyst Expectations For Eton Pharmaceuticals's Future

Critical Insights From Eton Pharmaceuticals Analyst Ratings: What You Need To Know

SWK Holdings Provides Portfolio Update

Domino's Pizza To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Friday